Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Bought by Raymond James & Associates

Raymond James & Associates grew its holdings in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 6.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 154,829 shares of the biopharmaceutical company’s stock after acquiring an additional 8,729 shares during the quarter. Raymond James & Associates’ holdings in Achieve Life Sciences were worth $638,000 as of its most recent SEC filing.

Separately, Manchester Financial Inc. lifted its holdings in shares of Achieve Life Sciences by 43.9% in the third quarter. Manchester Financial Inc. now owns 18,600 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 5,675 shares during the period. 33.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Lake Street Capital cut their price objective on Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 5th. Jonestrading assumed coverage on Achieve Life Sciences in a report on Wednesday, April 17th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Oppenheimer restated an “outperform” rating and issued a $18.00 price objective on shares of Achieve Life Sciences in a report on Monday, April 1st.

Achieve Life Sciences Stock Up 0.9 %

Shares of Achieve Life Sciences stock opened at $4.54 on Thursday. The stock’s fifty day moving average is $4.42 and its 200-day moving average is $4.41. The firm has a market capitalization of $155.50 million, a PE ratio of -2.97 and a beta of 1.32. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 4.02. Achieve Life Sciences, Inc. has a 12-month low of $3.03 and a 12-month high of $10.30.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.06. Equities analysts anticipate that Achieve Life Sciences, Inc. will post -0.94 earnings per share for the current year.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.